My personal opinion is that Pharma companies think this treatment may be too good to be true. That's why I think efficacy will be the crucible. Additionally, the hectic past ten years of Benitec may also add to their discounting. This is just my opinion, but I think once we see efficacy, things will change big time. But we need to get on a major exchange. That's indisputable.
Sanofi Signs Benitec's closest competitor Voyager for $845M, page-6
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)